AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 27072219
Drug: Concurrent chemoradiation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent chemoradiation (CRT) - 50 Gy in 25 fractions with weekly cisplatin
Trial: 25566589
Drug: Hyperbaric bupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperbaric bupivacaine (15 mg, 3 mL)
Trial: 25566589
Drug: Isobaric bupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isobaric bupivacaine (15 mg, 3 mL)
Trial: 20447305
Drug: Agmatine sulfate
RxNorm normalized name: palmatine
DrugBank: Agmatine (DB08838)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Agmatine sulfate 2.670 g/day for 14 days
Trial: 18797833
Drug: Immediate loading
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate loading of palatal implants (SB group) within 72 hours of insertion.
Trial: 18797833
Drug: Conventional loading
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional loading of palatal implants (KB group) after a 12-week healing period.
Trial: 15844302
Drug: Intrapericardial urokinase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrapericardial urokinase along with conventional treatment
Trial: 15844302
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment alone (including pericardiocentesis and drainage)
Trial: 12051573
Drug: Nitazoxanide (N)
RxNorm normalized name: Nitazoxanide
DrugBank: Nitazoxanide (DB00507)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nitazoxanide (N) 1 g
Trial: 12051573
Drug: Nitazoxanide (N)
RxNorm normalized name: Nitazoxanide
DrugBank: Nitazoxanide (DB00507)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nitazoxanide (N) 2 g
Trial: 12051573
Drug: Nitazoxanide (N)
RxNorm normalized name: Nitazoxanide
DrugBank: Nitazoxanide (DB00507)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nitazoxanide (N) 3 g
Trial: 12051573
Drug: Nitazoxanide (N)
RxNorm normalized name: Nitazoxanide
DrugBank: Nitazoxanide (DB00507)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nitazoxanide (N) 4 g
Trial: 10082778
Drug: High calcium
RxNorm normalized name: Nutritional Supplement Oral Liquid [ENSURE HIGH CALCIUM]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High calcium diet (4.67 g/L)
Trial: 10082778
Drug: Normal calcium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal calcium diet (2.0 g/L)
Trial: 10082778
Drug: High calcium
RxNorm normalized name: Nutritional Supplement Oral Liquid [ENSURE HIGH CALCIUM]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High calcium diet (4.67 g/L) and Normal calcium diet (2.0 g/L)
Trial: 30840961
Drug: Intermittent-full-standard-dose tamsulosin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent-full-standard-dose tamsulosin
Trial: 30840961
Drug: Low-dose tamsulosin
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose tamsulosin
Trial: 30840961
Drug: Full-standard-dose tamsulosin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Full-standard-dose tamsulosin (Control)
Trial: 28627980
Drug: Multi-intervention group
RxNorm normalized name: Parasedge Multi
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multi-intervention group (specialist-based, lifestyle modification and pharmacological treatment)
Trial: 26402011
Drug: ST101 (10,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ST101 (10, 60, or 120 mg QD)
Trial: 26402011
Drug: ST101 (120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ST101 (120 mg QD)
Trial: 19553296
Drug: Zinc supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zinc supplementation (5 mg/d for infants aged 2 wk to 6 mo; 10 mg/d for infants aged >6 mo)
Trial: 16892419
Drug: Paroxetine (maximum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paroxetine (maximum 60 mg by week 7)
Trial: 11289332
Drug: High-dose inhaled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose inhaled budesonide (1,600 microg daily)
Trial: 11289332
Drug: Oral methylprednisolone
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral methylprednisolone (1 mg/kg daily) plus medium-dose inhaled budesonide (800 microg daily)
Trial: 10557952
Drug: High-dose inhaled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose inhaled budesonide
Trial: 11289332
Drug: Oral methylprednisolone
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral methylprednisolone plus medium-dose inhaled budesonide
Trial: 2647896
Drug: Controlled-release oral
RxNorm normalized name: Afeditab CR
DrugBank: Nifedipine (DB01115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Controlled-release oral morphine sulfate (MSC) dosed at 8-, 10-, and 12-hour intervals
Trial: 2647896
Drug: Immediate-release morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate-release morphine sulfate (IRMS) dosed every four hours
Trial: 2647896
Drug: Prestudy analgesics
RxNorm normalized name: Analgesic Balm GRX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prestudy analgesics
Trial: 26177074
Drug: Indacaterol/Glycopyrrolate (27.5/15.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indacaterol/Glycopyrrolate (27.5/15.6 μg twice daily)
Trial: 26177074
Drug: Indacaterol (27.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indacaterol (27.5 μg twice daily)
Trial: 26177074
Drug: Glycopyrrolate (15.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glycopyrrolate (15.6 μg twice daily)
Trial: 16875154
Drug: Doxazosin (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxazosin (2 mg daily for 12 months)
Trial: 12947128
Drug: 570 kcal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 570 kcal carbohydrate rich supplement
Trial: 8668288
Drug: Piroxicam cinnamate
RxNorm normalized name: piroxicam cinnamate
DrugBank: Piroxicam cinnamate (DB15883)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Piroxicam cinnamate 30 mg tablets (Sinartrol), 1 tablet twice daily for 2 days followed by 1 tablet daily for 13 days
Trial: 8668288
Drug: Piroxicam cinnamate
RxNorm normalized name: piroxicam cinnamate
DrugBank: Piroxicam cinnamate (DB15883)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Piroxicam cinnamate 20 mg tablets, 1 tablet twice daily for 2 days followed by 1 tablet daily for 13 days
Trial: 2053016
Drug: Ivermectin (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ivermectin (150 to 220 mcg/kg, five single oral doses, one every six months)
Trial: 31862740
Drug: Usual care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual care (most commonly morphine)
Trial: 28917070
Drug: Daily consumption
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily consumption of sweets
Trial: 28917070
Drug: Weekly consumption
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Weekly consumption of carbonated beverages
Trial: 28917070
Drug: Daily consumption
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily consumption of carbonated beverages
Trial: 28917070
Drug: Weekly consumption
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Weekly consumption of energy drinks
Trial: 28917070
Drug: Daily consumption
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily consumption of energy drinks
Trial: 28917070
Drug: Association of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Association of daily sweets consumption with age
Trial: 28917070
Drug: Association of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Association of daily sweets consumption with carbonated beverages
Trial: 28917070
Drug: Association of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Association of daily sweets consumption with energy drinks
Trial: 28917070
Drug: Association of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Association of daily sweets consumption with high fat food
Trial: 28917070
Drug: Association of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Association of daily sweets consumption with BMI
Trial: 18167250
Drug: ALA 600
RxNorm normalized name: ALA
DrugBank: alpha-Linolenic acid (DB00132)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ALA 600 mg/d in normal saline 250 ml given by intravenous drip infusion once a day for 14 days
Trial: 18167250
Drug: Radix salviae
RxNorm normalized name: Salvia sclarea seed oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radix salviae 20 ml by intravenous drip infusion once a day for 14 days
Trial: 9703298
Drug: 0.025 mg
RxNorm normalized name: lisuride 0.025 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.025 mg of estradiol daily
Trial: 9703298
Drug: 0.05 mg
RxNorm normalized name: biotin 0.05 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.05 mg of estradiol daily
Trial: 9703298
Drug: 0.1 mg
RxNorm normalized name: biotin 0.1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1 mg of estradiol daily
Trial: 9703298
Drug: Transdermally administered
RxNorm normalized name: no vaccine administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermally administered estradiol
Trial: 8020522
Drug: iomeprol 150
RxNorm normalized name: IOMEPROL
DrugBank: Iomeprol (DB11705)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: iomeprol 150 mgI/ml
Trial: 8020522
Drug: iopamidol 150
RxNorm normalized name: Iopamidol
DrugBank: Iopamidol (DB08947)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: iopamidol 150 mgI/ml
Trial: 2644144
Drug: Cyclosporin (7.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclosporin (7.5 mg.kg‐1.day‐1)
Trial: 947969
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg terbutaline sulfate orally
Trial: 27755433
Drug: Postoperative 40 mg
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Postoperative 40 mg bromelain every 6 hours for 6 days (Group B)
Trial: 27755433
Drug: Preoperative 4 mg
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Preoperative 4 mg dexamethasone sodium phosphate as a submucosal injection (Group C)
Trial: 27755433
Drug: Preoperative 4 mg
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Preoperative 4 mg dexamethasone sodium phosphate as a submucosal injection plus postoperative 40 mg bromelain every 6 hours for 6 days (Group D)
Trial: 24633493
Drug: Metformin (Glucophage(®)
RxNorm normalized name: metformin Oral Tablet [Glucophage]
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Metformin (Glucophage(®) 500 mg) 1 tablet twice daily
Trial: 24633493
Drug: Sitagliptin (Januvia(®)
RxNorm normalized name: sitagliptin Oral Tablet [Januvia]
DrugBank: Sitagliptin (DB01261)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Sitagliptin (Januvia(®) 100 mg) 1 tablet/day
Trial: 21736768
Drug: Enriched virgin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enriched virgin olive oil (EVOO) (961·17 mg/kg oil)
Trial: 21736768
Drug: Control virgin
RxNorm normalized name: ALLERGENIC EXTRACT, QUECUS RUBRA, ALBA, AGRIFOLA, VIRGIN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control virgin olive oil (VOO) (288·89 mg/kg oil)
Trial: 17443133
Drug: Ruboxistaurin 96
RxNorm normalized name: RUBOXISTAURIN
DrugBank: Ruboxistaurin (DB11829)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ruboxistaurin 96 mg/day orally
Trial: 14594866
Drug: 100 g
RxNorm normalized name: Berri-Freez 4.5 GM per 100 GM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 g of carbohydrates (CHO)
Trial: 26625709
Drug: Calcium and
RxNorm normalized name: Calcium and Magnesium
DrugBank: Calcium carbonate (DB06724)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Calcium and vitamin D-fortified snack bar (2000 mg/d Ca and 25 µg/d vitamin D) consumed 2 snack bars/d for 9 weeks
Trial: 22431837
Drug: 800 IU/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 800 IU/d of vitamin E (α‐tocopherol) plus 500 mg/d of vitamin C plus 900 mg/d of α‐lipoic acid (E/C/ALA)
Trial: 22431837
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg of coenzyme Q 3 times/d
Trial: 19192127
Drug: All medication
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All medication arms
Trial: 18278696
Drug: Evidence-based medicine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Evidence-based medicine (ebm) implementation in oncology
Trial: 2175584
Drug: 8 mg
RxNorm normalized name: alloin 8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 mg perindopril
Trial: 17676252
Drug: Illicit drug
RxNorm normalized name: Illicium difengpi bark extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Illicit drug use
Trial: 10980912
Drug: Aggressive treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aggressive treatment of dyslipidemia using lovastatin
Trial: 8256106
Drug: Lariam (mefloquine)
RxNorm normalized name: mefloquine hydrochloride Oral Tablet [Lariam]
DrugBank: Mefloquine (DB00358)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lariam (mefloquine) 250 mg on alternate weeks
Trial: 8256106
Drug: Fansidar (sulfadoxine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fansidar (sulfadoxine and pyrimethamine) one tablet weekly
Trial: 31898526
Drug: Hand-washing with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hand-washing with soap at key times and weekly nail clipping
Trial: 26701977
Drug: 1.25 mmol/L
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.25 mmol/L Ca (1.25 Ca), n=212
Trial: 26701977
Drug: 1.75 mmol/L
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.75 mmol/L Ca (1.75 Ca), n=213
Trial: 25683256
Drug: Salsalate (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salsalate (3 g/day for 7 days)
Trial: 12692782
Drug: Continuous androgen
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous androgen deprivation (CAD) therapy
Trial: 24386861
Drug: Standard intermittent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard intermittent androgen deprivation (IAD) therapy
Trial: 24386861
Drug: Modified intermittent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modified intermittent androgen deprivation (IAD) therapy
Trial: 18821290
Drug: Testosterone therapy
RxNorm normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Testosterone therapy (intramuscular injections of testosterone enanthate every three weeks for 12 months)
Trial: 12558678
Drug: Preoperative neoadjuvant
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Preoperative neoadjuvant therapy for early stage locally advanced breast cancer
Trial: 3245859
Drug: 0.05% clobetasol
RxNorm normalized name: CLOBETASOL PROPIONATE 0.5 mg in 1 g TOPICAL CREAM [Clobetasol Propionate Cream, 0.05% Clobetasol Propionate Cream, 0.05%]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.05% clobetasol 17‐propionate cream
Trial: 8722606
Drug: 0.05% clobetasol
RxNorm normalized name: CLOBETASOL PROPIONATE 0.5 mg in 1 g TOPICAL CREAM [Clobetasol Propionate Cream, 0.05% Clobetasol Propionate Cream, 0.05%]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.05% clobetasol 17‐propionate ointment
Trial: 140084
Drug: 0.1% triamcinolone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1% triamcinolone acetonide cream
Trial: 7065664
Drug: 0.1% triamcinolone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1% triamcinolone acetonide ointment
Trial: 8722606
Drug: 0.05% clobetasol
RxNorm normalized name: CLOBETASOL PROPIONATE 0.5 mg in 1 g TOPICAL CREAM [Clobetasol Propionate Cream, 0.05% Clobetasol Propionate Cream, 0.05%]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.05% clobetasol 17‐propionate cream and ointment
Trial: 1548248
Drug: Clonidine (approximately
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clonidine (approximately 0.005 mg/kg/day)
Trial: 31572243
Drug: Autonomy-enhancing treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Autonomy-enhancing treatment (AET), 15-session group-based
Trial: 29873089
Drug: Opioid misuse
RxNorm normalized name: OPIOIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Opioid misuse (defined as use of illicit or prescription opioids without a prescription or not as directed in the previous 6 months)
Trial: 26714287
Drug: CYP3A5 genotype-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CYP3A5 genotype-based tacrolimus dosing
Trial: 20393454
Drug: Standard daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard daily regimen of tacrolimus
Trial: 18592826
Drug: Extra-fine hydrofluoroalkane-beclomethasone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extra-fine hydrofluoroalkane-beclomethasone (200 microg daily via an Autohaler)
Trial: 18592826
Drug: Fluticasone dry
RxNorm normalized name: fluticasone Dry Powder Inhaler
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluticasone dry powder inhaler (200 microg daily via a Diskus)
Trial: 16117451
Drug: Conventional dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional dose of 300 IU/kg heparin for total body weight (TBW)
Trial: 16117451
Drug: Dose of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose of 300 IU/kg heparin for calculated lean body mass (LBM)
Trial: 12297361
Drug: Amoxycillin-clavulanate 2000/125
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxycillin-clavulanate 2000/125 mg, twice daily
Trial: 12297361
Drug: Amoxycillin-clavulanate 1000/125
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxycillin-clavulanate 1000/125 mg, three times daily
Trial: 10726961
Drug: Terlipressin (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terlipressin (2 mg bolus infusion)
Trial: 9166360
Drug: Oxytocin administration
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oxytocin administration to stimulate the pregnant uterus or ripen the cervix
Trial: 8445237
Drug: Malotilate (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Malotilate (500 mg three times a day)
Trial: 3088739
Drug: hydroflumethiazide 50
RxNorm normalized name: hydroflumethiazide 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hydroflumethiazide 50 mg, Rauwolfia serpentina 50 mg and potassium chloride 625 mg (HFRK)
Trial: 3088739
Drug: clopamide 5
RxNorm normalized name: clopamide 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: clopamide 5 mg, reserpine 0.1 mg and dihydroergocristine 0.5 mg (CRE)
Trial: 20194698
Drug: SP+AS+PQ (0.75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SP+AS+PQ (0.75 mg/kg of body weight)
Trial: 16204902
Drug: Immediate anti-H.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate anti-H. pylori treatment and oral ferrous sulfate
Trial: 16204902
Drug: Delayed anti-H.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed anti-H. pylori treatment and oral ferrous sulfate
Trial: 16204902
Drug: Only oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Only oral ferrous sulfate (H. pylori negative patients)
Trial: 16204902
Drug: Delayed anti-H.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed anti-H. pylori treatment after one month
Trial: 12432836
Drug: Epinephrine injection
RxNorm normalized name: epinephrine Injection
DrugBank: Epinephrine (DB00668)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Epinephrine injection (1:10,000)
Trial: 12432836
Drug: Epinephrine plus
RxNorm normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Epinephrine plus sclerosing agent
Trial: 8564089
Drug: Cyclosporin A
RxNorm normalized name: Cyclosporin A
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclosporin A (CsA) 5 mg/kg/d for 36 weeks
Trial: 26340744
Drug: Dabrafenib plus
RxNorm normalized name: Dabrafenib
DrugBank: Dabrafenib (DB08912)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Dabrafenib plus trametinib (150 mg dabrafenib twice daily combined with 2 mg trametinib once daily)
Trial: 26340744
Drug: Dabrafenib plus
RxNorm normalized name: Dabrafenib
DrugBank: Dabrafenib (DB08912)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Dabrafenib plus trametinib (after adjustment for treatment switching)
Trial: 26340744
Drug: Dabrafenib alone
RxNorm normalized name: Dabrafenib
DrugBank: Dabrafenib (DB08912)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Dabrafenib alone (before adjustment for treatment switching)
Trial: 27082108
Drug: Tamsulosin 0.4
RxNorm normalized name: tamsulosin 0.4 mg oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tamsulosin 0.4 mg daily
Trial: 21404197
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (hydration and analgesic on demand)
Trial: 18245999
Drug: 0.5% Marcain
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5% Marcain (96 mL, 2 mL/h for 48 hours)
Trial: 9605669
Drug: Oral glutamine
RxNorm normalized name: Glutamine
DrugBank: L-Glutamine (DB00130)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral glutamine (GLN) 0.5 g/kg/day during MTX neoadjuvant therapy
Trial: 9605669
Drug: Methotrexate (MTX)
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Methotrexate (MTX) 40 mg/m2 to 100 mg/m2 weekly for 3 weeks
Trial: 8273984
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg of omeprazole daily
Trial: 8273984
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg of omeprazole daily